Skip to main content

Market Overview

Why Egalet Investors Should Expect FDA Approval On Arymo By Year-End

Share:

Egalet Corp’s (NASDAQ: EGLT) proprietary abuse-deterrent extended-release morphine formulation, Arymo ER, will likely be approved by the end of this year, Cantor Fitzgerald’s Chiara Russo said in a report.

She maintained a Buy rating on the company, with a price target of $21.

Arymo’s potential approval by year-end fits “the FDA's pattern of taking their time to tailor each AD opioid label,” Russo wrote. Once the approval comes, Egalet would need to invest an additional $40 million in debt financing on the commercial front in order to begin internalizing its salesforce.

If approved, Arymo should have “the broadest label of the currently approved ER morphine formulations, which we maintain will be a commercial competitive advantage,” Russo commented.

The analyst expects shareholders to focus on Egalet’s top-line revenue in the next 12-months as well as the Phase 3 readout of Egalet-002, which is scheduled for the first half of 2017.

Egalet reported its Q3 revenue at $4.7 million, in-line with expectations. EPS came in at ($1.10), missing Cantor’s estimate of ($0.83).

“The difference was mainly due to one time increase in R&D spend and interest expenses dues to debt extinguishment,” Russo noted. Egalet ended the year with $101.2 million in cash.

Latest Ratings for EGLT

DateFirmActionFromTo
Aug 2018JMP SecuritiesMaintainsMarket OutperformMarket Outperform
Mar 2018Cantor FitzgeraldMaintainsOverweightOverweight
Jan 2018StifelDowngradesBuyHold

View More Analyst Ratings for EGLT

View the Latest Analyst Ratings

 

Related Articles (EGLT)

View Comments and Join the Discussion!

Posted-In: Cantor Fitzgerald Chiara RussoAnalyst Color Long Ideas Reiteration Analyst Ratings Trading Ideas

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com